---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001299"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T22:12:50.989650+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026

## Summary
- Moderna to pay $950M upfront by July 8, 2026, plus $1.3B contingent on affirming rejection of Section 1498 defense.
- Arbutus receives 20% of proceeds after litigation costs under its Genevant license; total potential $2.25B.
- Arbutus evaluating a return of capital to shareholders in Q3 2026, tied to the upfront payment.
- Settlement includes judgment of infringement and no invalidity on four patents; global license for SM-102 LNP mRNA vaccines.

## SEC filing metadata
- accession: 0001171843-26-001299
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001299
- JSON: https://secwatch.observer/filing/0001171843-26-001299.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001299.txt

## Source-grounded claims
- claim_id: 8fc31b6220906dce47f4a406775c43f7bf172d2d
  claim: Arbutus Biopharma Corp entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, Moderna) valued at $950.0 million noncontingent lump sum payment (effective 2026-03-03).
  evidence_excerpt: On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Arbutus/Genevant and Moderna pending in the U.S. and internationally relating to Moderna’s unauthorized use of Arbutus/Genevant’s lipid nanoparticle (“LNP”) delivery technology in its vaccines, including Spikevax® (the “LNP Litigation”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.